» Articles » PMID: 30504295

Treatment Approach for the Older, Unfit Patient with Myeloma from Diagnosis to Relapse: Perspectives of a European Hematologist

Overview
Specialty Hematology
Date 2018 Dec 4
PMID 30504295
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Mrs. A. is a 73-year-old woman who has developed increasing fatigue and lower back pain over the past year. The pain limits her exercise tolerance such that she can now walk only 1 block. She is a retired schoolteacher who does volunteer efforts in her community but has limited her activities due to fatigue. Karnofsky performance status is 70%. She has a history of chronic hypertension treated with a diuretic, adult-onset diabetes mellitus treated with metformin, and hypothyroidism treated with levothyroxine. Initial evaluation reveals anemia, renal dysfunction, an elevated total protein, and an L2 compression fracture on lumbosacral radiographs. Results of initial and subsequent evaluation are shown below, and she is referred to a hematologist for further evaluation, which revealed the following: calcium 9.0 mg/dL, creatinine 3.2 mg/dL with estimated creatinine clearance using the Modification of Diet in Renal Disease equation of 15 mL/min, hemoglobin 9.6 g/dL, total protein 11 g/dL, albumin 3.2 g/dL, immunoglobulin A (IgA) λ M protein 6.8 g/dL, total IgA 7.2 g/dL, IgG 0.4 g/dL, IgM 0.03 g/dL, free κ <0.01 mg/L, free λ 1000 mg/L, free light chain ratio <0.01, β-2-microglobulin 4.2, viscosity 3.0, lactate dehydrogenase 200 U/L, urine protein electrophoresis: 125 mg/dL with 30% M protein, and urine immuno-electrophoresis: λ light chain. Skeletal bone survey showed lytic lesions in femurs and humeri and diffusely in ribs bilaterally as well as compression fractures at T4, T6, and L2. Bone marrow biopsy revealed λ-restricted plasma cells comprising 50% of the bone marrow core. Fluorescence in situ hybridization testing on marrow showed that del(17p) was present in 80% of the plasma cells. Mrs. A. is informed of the diagnosis of multiple myeloma and the need for therapy. She requests consultation with 2 of the leading world experts. However, she wants to be treated near her home and does not want treatment on a clinical trial.

Citing Articles

Front-line treatment of multiple myeloma.

Cavo M, Tacchetti P, Zamagni E Hemasphere. 2022; 3(Suppl).

PMID: 35309768 PMC: 8925677. DOI: 10.1097/HS9.0000000000000242.


Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review.

Imtiaz H, Khan M, Ehsan H, Wahab A, Rafae A, Khan A Onco Targets Ther. 2021; 14:4941-4960.

PMID: 34629878 PMC: 8493667. DOI: 10.2147/OTT.S317570.


Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.

Cook G, Larocca A, Facon T, Zweegman S, Engelhardt M Leukemia. 2020; 34(9):2285-2294.

PMID: 32555295 PMC: 7449877. DOI: 10.1038/s41375-020-0918-6.


Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?.

Engelhardt M, Yong K, Bringhen S, Wasch R Haematologica. 2019; 104(11):2128-2131.

PMID: 31666342 PMC: 6821633. DOI: 10.3324/haematol.2019.228684.

References
1.
Milani P, Rajkumar S, Merlini G, Kumar S, Gertz M, Palladini G . N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016; 91(11):1129-1134. PMC: 5129512. DOI: 10.1002/ajh.24532. View

2.
Avet-Loiseau H, Facon T . Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. Leukemia. 2018; 32(6):1267-1276. PMC: 5990526. DOI: 10.1038/s41375-018-0098-9. View

3.
Lawton M, Brody E . Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969; 9(3):179-86. View

4.
Palumbo A, Bringhen S, Mateos M, Larocca A, Facon T, Kumar S . Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015; 125(13):2068-74. PMC: 4375104. DOI: 10.1182/blood-2014-12-615187. View

5.
Hulin C, Belch A, Shustik C, Petrucci M, Duhrsen U, Lu J . Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. J Clin Oncol. 2016; 34(30):3609-3617. DOI: 10.1200/JCO.2016.66.7295. View